期刊文献+

冠状动脉易损斑块及其形态学检测技术的新认识 被引量:2

New recognition of vulnerable plaques in coronary artery and its detection technology of morphology
下载PDF
导出
摘要 冠心病患者发生严重急性冠状动脉事件约70%是由易损斑块(VP)所致。不稳定斑块的破裂是急性冠状动脉综合征(ACS)发生的核心机制,其较冠状动脉狭窄程度及病变范围更能反映冠心病患者发生急性心血管事件。现代影像学技术的进展,特别是血管内超声(IVUS)及光学相干断层成像(OCT)对识别和判断VP的形态学特征,包括斑块的形态、成分,甚至功能状态提供了快速、可靠的信息支持,在诊断和评价冠状动脉斑块方面,高分辨率的0CT检测水平已近似于组织学检测水平。该文就VP形态学检测技术的进展和认识作一简要综述。 About 70% of severe acute coronary events in patients with coronary artery disease are caused by vulnerable plaques (VP). The rupture of unstable plaques is core mechanism of occurrence of acute coronary syndrome (ACS) and which effects is more important than that of degrees of coronary artery stenosis and ranges of illness with coronary artery in occurrence of acute cardiovascular events. The modem progress of imaging technology, espe- cially intravascular ultrasound (IVUS) and optical coherence tomography (OCT), provides supports of fast and reliable information for identification and judgment of morphologial features of VP, including form, composition, and even function condition of VP. In diagnosis and evaluation of coronary artery plaques, the detection level of OCT with high distingnish rate is nearing the detection level of the histology, and then possessed with important clinical siginificance. In this paper,the progress on detection technology of VP morphology and new recognition are reviwed simply.
出处 《中国临床新医学》 2012年第2期184-186,共3页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词 冠状动脉疾病 易损斑块 形态学 影像技术 Coronary artery disease Vulnerable plaque Morphology Imaging technology
  • 相关文献

参考文献20

  • 1Lewis SJ.Prevention and treatment of atherosclerosis:a practitioner's guide for 2008[J].Am J Med,2009,122(1 Suppl):S38-S50.
  • 2Virmani R,Kolodgie FD,Burke AP,et al.Lessons from sudden coronary death:a comprehensive morphological classification scheme for atherosclerotic lesions[J].Arterioscler Thromb Vasc Biol,2000,20(5):1262-1275.
  • 3Davì G,Patrono C.Platelet activation and atherothrombosis[J].N Engl J Med,2007,357(24):2482-2494.
  • 4Peter Libby,严武(整理).从ACS发病机制新进展看临床管理[N].中国医学论坛报,2010-07-29(C7).
  • 5Naghavi M,Libby P,Falk E,et al.From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:Part Ⅰ[J].Circulation,2003,108(14):1664-1672.
  • 6Schwartz SM,Galis ZS,Rosenfeld ME,et al.Plaque rupture in humans and mice[J].Arterioscler Thromb Vasc Biol,2007,27(4):705-713.
  • 7李熖生.如何干预动脉粥样硬化?[N].中国医学论坛报,2010-08-05(C5).
  • 8Varnava AM,Mills PC,Davies MJ.Relationship between coronary artery remodeling and plaque vulnerability[J].Circulation,2002,105(8):939-943.
  • 9Motoyama S,Kondo T,Sarai M,et al.Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes[J].J Am Coll Cardiol,2007,50(4):319-326.
  • 10Frey AW,Hodgson JM,Müller C,et al.Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter:results from the randomized Strategy for Intracoronary Ultrasound-guided PTCA and Stenting (SLPS) trial[J].Circulation,2000,102(20):2497-2502.

二级参考文献32

  • 1牛玉宏,许从峰,史剑慧,葛均波.感染负荷与粥样硬化形成及斑块性质的相关性[J].中华心血管病杂志,2005,33(4):303-306. 被引量:8
  • 2Naghavi M,Libby P,Falk E,et al. From vulnerable plaque to vulnerable patient: a call for new definition and risk assessment strategies; part I [J]. Circulation, 2003,108 (14) : 1664-1672.
  • 3Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction[J]. Circulation, 1997,96(2) : 404-407.
  • 4Von der Thusen JH, Kuiper J, van Berkel TJ, et al. Interleukins in atherosclerosis: molecular pathways and therapeutic potential[J]. Pharmacol Rev,2003,55(1): 133-166.
  • 5Klouche M, Rose-John S, Sehmiedt W, et al. Enzymatically degraded, nonoxidized LDL Induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation[J]. Circulation, 2000,101 (15) : 1799-1805.
  • 6Haverkate F,Thompson SG,Pyke SD,et al. Production of Creactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group[J]. Lancet, 1997,349(9050) :462-466.
  • 7Corsetti JP,Rainwater DL, Moss A J, et al. High lipoprotein- associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients[J]. Clin Chem, 2006,52(7) : 1331-1338.
  • 8Serruys PW,Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque [J]. Circulation, 2008,118(11):1172-1182.
  • 9Blankenberg S, Rupprecht J, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase' 9 and prognosis of patients with cardiovascular disease[J]. Circulation, 2003, 107 (12) : 1579- 1585.
  • 10Frey AW, Hodgson JM,Muller C, et al. Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter: results from the randomized Strategy for Intracoronary Ultresound-guided PTCA and Stenting (SIPS) trial [J]. Circulation, 2000,102 (20) : 2497-2502.

共引文献5

同被引文献20

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部